ClinicalTrials.gg
Not yet recruitingNCT07940062COMPAREUpdated Nov 16, 2026

Co-Existent Endometrial and Ovarian Carcinoma: Molecular Stratification for Pathologic Reporting and Clinical Management

A Phase 2 interventional study of Treatment De-escalation and Additional Treatment in Co-existent Endometrial and Ovarian Carcinoma, Ovarian Carcinoma and Endometrial Carcinoma (EC), sponsored by British Columbia Cancer Agency. Not yet recruiting at 1 site in Canada. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by British Columbia Cancer Agency · Phase 2, Interventional, and Treatment

Updated Nov 16, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
90
Allocation
Non-randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 273 studies in Ovarian Neoplasms with a site in Canada — 49 open to participants now, 89 under way, 27 of them phase 3. Ovarian Neoplasms · Canada.

Planned enrollment
148th of 239
90 · median 136
Started
2026
with 11 others
Phase 2
90 of 273
11 open now
Primary completion
2032-10
later than 85 of 88 live
Registered
272nd of 273
by date
Lead sponsor
6 of 273
British Columbia Cancer Agency

Among the 273 studies in Ovarian Neoplasms with a site in Canada, this one is the 148th largest by planned enrollment of the 239 interventional ones that give a count, is one of 12 that started in 2026, is one of 90 in phase 2, reaches primary completion later than 85 of the 88 other live ones, and was the 272nd registered.

Ovarian Neoplasms

3,387 studies on the registry are indexed under Ovarian Neoplasms; 792 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

49 of the 273 studies in Ovarian Neoplasms with a site in Canada are open now. Recruiting first, the newest first:

44 more — sign in →

All 49 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 605 Ovarian Neoplasms studies recruiting now, 442 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 273 studies in Ovarian Neoplasms with a site in Canada, or all of them as a file.
02

Study summary

Patients with co-existent endometrial and ovarian carcinomas (CEOCs) are treated inconsistently due to a lack of clear standardized treatment guidelines. Patients may be over-treated and face substantial physical side effects and financial challenges due to additional chemotherapy or radiation appointments. Previous retrospective research has shown that using specific molecular and pathologic criteria to stratify patients' CEOC tumours can identify patients at very low risk of cancer recurrence (during an average 6 years of follow-up), with no demonstrated benefit of additional treatment after surgery.

The goal of this study is to determine the safety of receiving no additional treatment (i.e. no chemotherapy or radiation) after surgery in patients diagnosed with a co-existent endometrial and ovarian cancer (CEOC) meeting highly selective molecular and pathologic criteria. Patients with CEOC who also meet predefined molecular criteria (low risk POLEmut, ER+NSMP, or MSH2/MSH6/PMS2 loss without MLH1 promoter hypermethylation in the endometrium and ovary) and pathology criteria (see schema) are eligible to participate. Patients may choose, or be directed by their physician to receive no additional treatment after surgery or to receive additional treatment.

To determine the safety of this approach, the study team will evaluate pelvic recurrence (primary) rate, as well as vaginal and distant recurrences, recurrence-free and disease- specific, and overall survival, quality of life, and health economic metrics among patients who do, and do not receive additional treatment after surgery.

Study design is pragmatic, designed to match recommended standard of care as closely as possible. Patients will have regular follow-up appointments with their oncologist every 4 months for 3 years as part of their medical care. During this time, patients will complete quality of life surveys at baseline, 4, 12, 24, and 36 months. Baseline imaging, and imaging at completion of 3-years are required.

Read the detailed description

PURPOSE: To determine the safety of de-escalated/optimized adjuvant treatment of patients with CEOC directed by tumor molecular status and strictly defined pathology criteria.

HYPOTHESIS: Molecular classification in combination with carefully selected and restricted pathological features will identify a subset of patients with CEOCs who are at very low risk of disease recurrence and are candidates for de-escalated/optimized adjuvant therapy.

JUSTIFICATION: CEOC patients are often given chemotherapy +/- pelvic radiation, despite unclear benefit and substantial toxicity from short and long termshort- and long-term treatment-related side effects, such as neuropathy, fatigue and cognitive issues. Overtreatment also results in financial challenges for patients from loss of income, travel expenses related to many appointments and delayed return to work. Although the World Health Organization created a new substage within the endometrial cancer staging system to support the delivery of less (or no) treatment for CEOC patients based on pathology criteria that supports favourable outcomes, studies have shown that molecular features of endometrial cancer can also be used to identify a subset of CEOC patients at very low risk of recurrence who can be directed to treatment de-escalation. In order to further evaluate these findings and change clinical practice, a prospective trial is needed to assess the safety of de-escalated treatment for CEOC patients.

RESEARCH DESIGN: This is a phase II, prospective, multi-centre, trial where pathologic and molecular features will be used to identify patients who can be offered de-escalated therapy. Molecular classification- assessing immunohistochemistry for MMR, p53, and ER status in the endometrium and ovarian tumors will be performed. Next generation sequencing for POLE mutation status is needed at least in the endometrial sample. Molecular criteria to define low risk CEOCs will include POLEmut, ER strong + NSMP, and MSH2/MSH6 or PMS2 loss (MMRd without MLH1 promoter hypermethylation) and provided pathologic criteria are also met would enable patients to be considered for de-escalation. Intermediate and high risk carcinomas, encompassing MLH1 promoter methylated, ER-negative NSMP and p53abn CEOCs would not be enrolled.

The first site will open in BC, Canada. Due to this rare patient population, other high-volume national and international centers will be sought. Collaborating centers will be selected based on access to molecular testing and interest in providing their CEOC patients with the opportunity to participate in this trial.

The aim of this trial is to assess the safety of de-escalated adjuvant treatment in CEOC patients. Patients that fit the eligibility criteria will have the option of choosing to receive treatment de-escalation (no chemotherapy or radiation) vs. additional treatment (chemotherapy +/- radiation) following their primary staging surgery.

Recruitment will take place over 3 years from November 1, 2026 - November 1, 2029. Participants will be followed for 3 years after their enrollment after surgery.

Baseline Measures:

  1. Imaging: If a patient has not had imaging performed on their chest, abdomen and pelvis within 60 days prior to trial enrollment, the patient's gynecologic oncologist will order this imaging to be done within five weeks after trial enrollment. Accepted imaging modalities are (CT, chest x-ray, MRI, PET). Note that imaging prior to surgery is standard of care.
  2. Questionnaires: Upon signing the consent form (baseline), patients will be prompted to complete 3 questionnaires about their quality of life and their thoughts regarding their treatment decision (active surveillance vs. additional treatment):

1. EORTC QLQ-30 2. FCRI-SF 3. EQ-5D-5L

These questionnaires will be administered through an online platform for the participant to complete on their own device or on a tablet/laptop provided by the study team. Physical copies will be made available upon patient request.

If patient's do not speak English or feel comfortable completing the questionnaires in English, the study coordinator will attempt to obtain these questionnaires in the patient's preferred language.

Follow-Up Measures:

  1. Imaging: Imaging of the patient's chest, abdomen, and pelvis will be ordered 36 months after enrollment. Although the exact timepoints after surgery are up to the doctor's discretion, additional imaging post-surgery is a part of a patient's standard of care.
  2. Questionnaires: Patients will complete the three questionnaires listed above at enrollment, 4, 12, 24, \& 36 months after enrollment. These questionnaires will be administered at patients follow-up appts or through an online platform.
  3. Symptom History \& Physical exam: It is standard of care to review patient symptoms and perform abdominal and pelvic examinations during their follow-up appts. This will be recorded by the patient's oncologist within their clinical note. The local study coordinator will review the clinic note and record the outcomes of this symptom review and physical exam within that patient's record on the data collection platform.

Recurrence:

If a patient's cancer recurs within the 3 year follow-up period, patients will undergo the following study procedures annually from the date of recurrence:

  1. Two questionnaires (EORTC QLQ-30 \& EQ-5D-5L)
  2. Symptom History \& Physical exam

STATISTICAL ANALYSIS: Assuming 68 patients with molecularly stratified CEOC (exclusion of exclusion of MMRd with MLH1 immunohistochemistry loss or MLH1 promoter hypermethylation, p53abn and NSMP ER negative-low) are accrued over 3 years and followed for 3 years, the total person-years of follow-up would be 306 and the upper 95% confidence limit for the true 3-year pelvic recurrence rate would be 7% when the observed 3-year pelvic recurrence rate is 4% from CEOCs in this cohort. Therefore, a true 3-year pelvic recurrence rate of 7%, which for this trial is considered unacceptably high, can be ruled out with 95% confidence in this cohort. Allowing that \~5% of patients may be lost to follow up and 25% of patients may not elect to undergo de-escalated therapy (e.g., will be treated, not counting towards n=68), we estimate needing to enroll \~90 patients to yield 68 evaluable receiving de-escalation. As the statistical analysis has been designed to demonstrate the safety of de-escalation within the group of patients that received no additional treatment, patients who receive adjuvant treatment following surgery are not part of this trial's statistical analysis.

03

Conditions studied

  • Co-existent Endometrial and Ovarian Carcinoma
  • Ovarian Carcinoma
  • Endometrial Carcinoma (EC)

Keywords

  • Treatment De-escalation
  • Co-existent endometrial and ovarian carcinoma (CEOC)
  • Synchronous
  • Prospective Phase II
  • Molecular classification
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Had primary surgery consisting of hysterectomy (any surgical approach) and bilateral salpingo-oophorectomy.
  • Lymph node dissection can be performed as per institutional practice (sentinel node or full).
  • Had no macroscopic residual disease after surgery.

Meet the molecular and pathological criteria (1, 2, or 3) as determined or identified by their local oncologist and pathologist:

  1. (Molecular) NSMP ER strong positive:

    1. Endometrial site

      • Low grade endometrioid (grade 1-2)
      • \<50% myometrial invasion (FIGO 2009 stage IA)
      • Absence of substantial lymphovascular invasion (LVI)
    2. Ovarian site

      • Low grade endometrioid (grade 1-2)

        • bilateral (stage IB),
        • intraoperative spill (stage ICI),
        • preoperative rupture (stage IC2),
        • surface involvement (stage IC2)
  2. (Molecular) POLEmut

    1. Endometrial site

      • FIGO 2009 stage IA or IB (regardless of grade, histotype, myoinvasion or LVI)
    2. Ovarian site

      • Low grade endometrioid (grade 1-2)

        • bilateral (stage IB),
        • intraoperative spill (stage ICI),
        • preoperative rupture (stage IC2),
        • surface involvement (stage IC2),
  3. (Molecular) MSH2, MSH6, or PMS2 loss (MMRd without MLH1 promoter hypermethylation)

    1. Endometrial site

      • FIGO 2009 stage IA or IB (regardless of grade, histotype, myoinvasion or LVI)
    2. Ovarian site

      • Low grade endometrioid (grade 1-2)

        • bilateral (stage IB),
        • intraoperative spill (stage ICI),
        • preoperative rupture (stage IC2),
        • surface involvement (stage IC2),

Exclusion criteria

Exclusion Criteria:

  • Individuals with MMRd MLH1 promoter hypermethylation or p53abn status in their ovarian or endometrial tumour.
  • Individuals with ER negative-low status in the endometrium.
  • Individuals with any additional sites of .
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    Treatment De-escalation

    After undergoing surgery, patients elect to not receive any further treatment (such as radiation or chemotherapy) to treat their cancer. Instead their condition will be closely followed by their oncologist for 3 years.

    Other: Treatment De-escalation

  • Other
    Additional Treatment

    After undergoing surgery, patients elect to receive additional treatment (such as radiation or chemotherapy) to treat their cancer. The type of additional treatment received will be determined by the patient's oncologists in conjunction with the patient. These patients will be closely followed by their oncologist for 3 years.

    Other: Additional Treatment

Interventions

  • OtherTreatment De-escalation

    Receiving no further treatment (such as radiation or chemotherapy) after surgery to treat their CEOC.

    Also known as: Active surveillance

  • OtherAdditional Treatment

    Receive additional treatment (such as radiation or chemotherapy) after surgery to treat their CEOC.

    Also known as: Adjuvant treatment, Additional post-surgical treatment

06

What researchers measure

Primary outcomes

  1. Pelvic recurrence rate of participants in the treatment de-escalation group

    The number of patients who participated in the treatment de-escalation group and developed a recurrence of their cancer in their pelvis within the 3-year follow-up period. Evidence of recurrence may be based on clinical exam, imaging, and/or histologic evidence/biopsy.

    Time frame: Enrollment to 3 years

Secondary outcomes

  1. The rate of isolated vaginal recurrence and distant metastases.

    The number of patients who participated in the treatment de-escalation group and developed a recurrence of their cancer within their vagina and/or developed distant metastases within the 3-year follow-up period. Evidence of recurrence may be based on clinical exam, imaging, and/or histologic evidence/biopsy.

    Time frame: Enrollment to 3 years

  2. Recurrence-free survival (RFS)

    Recurrence-free survival is defined as the time from surgery/staging until CEOC disease recurrence. This measure will be obtained through clinical follow-up e.g., symptom review \& physical examinations, performed by the local investigators and the date of recurrence will be recorded by the local study coordinator. This survival measure will be calculated for patients in the treatment de-escalation group and the additional treatment group.

    Time frame: Date of surgery to 3 years after study enrollment

  3. Worries about cancer recurrence

    The Fear of Cancer Recurrence Inventory - Short Form (FCRI-SF) will be administered to patients to understand their level of worry/fear they have about their cancer recurring over the past month. On the FCRI-SF, a lower score represents little fear or worry of a recurrence whereas a higher score represents greater fear or worry of a recurrence.

    Time frame: At enrollment, then at 4, 12, 24, and 36 months after enrollment.

  4. Health economic impact of patients' post-surgery treatment decision

    The EuroQol EQ-5D-5L questionnaire will be administered to patients to obtain their health related utility scores to understand the health economic impact of treatment de-escalation compared to receiving additional adjuvant treatment. Patients will indicate their health status on a scale from 0 (worst health status) to 100 (best health status).

    Time frame: At enrollment, then at 4, 12, 24, and 36 months after enrollment.

  5. Disease specific survival (DSS)

    Disease specific survival is defined as the time from surgery/staging until death from CEOC disease. This measure will be obtained through clinical follow-up e.g., symptom review \& physical examinations, performed by the local investigators and the date of recurrence will be recorded by the local study coordinator. This survival measure will be calculated for patients in the treatment de-escalation group and the additional treatment group.

    Time frame: Date of surgery to 3 years after study enrollment

  6. Overall survival (OS)

    Overall survival is the time from surgery/staging until death from any cause (including death from CEOC disease or death from other non-cancer related causes). This measure will be obtained through clinical follow-up e.g., symptom review \& physical examinations, performed by the local investigators and the date of recurrence will be recorded by the local study coordinator. This survival measure will be calculated for patients in the treatment de-escalation group and the additional treatment group.

    Time frame: Date of surgery to 3 years after study enrollment

  7. Health-related quality of life

    The 30-item EORTC QLG Core Questionnaire (EORTC QLQ-C30) will be administered to patients to measure their quality of life throughout the trial. This questionnaire contains different scales to evaluate patients' function, symptoms, and global health status. Raw scores from the questionnaire are converted to a standardized scale from 0 - 100, with a higher score for the function and global health status scales representing a better level of functioning and a higher score for the symptom scale representing a higher level of symptoms experienced.

    Time frame: At enrollment, then at 4, 12, 24, and 36 months after enrollment.

07

Study locations

1 site
08

References and documents

Publications

  • Keyhanian K, Gilks CB, Mathew EP, Mack T, Sekhon H, Lo B, Greenstreet P, Grondin K, McAlpine JN, Jamieson A. Coexistent Endometrial and Fallopian Tube Carcinoma: Molecular and Pathological Features for Risk Stratification. Mod Pathol. 2026 Aug;39(8):101030. doi: 10.1016/j.modpat.2026.101030. Epub 2026 Jun 19. PubMed 42320759 ↗
  • Post CCB, Stelloo E, Smit VTHBM, Ruano D, Tops CM, Vermij L, Rutten TA, Jurgenliemk-Schulz IM, Lutgens LCHW, Jobsen JJ, Nout RA, Crosbie EJ, Powell ME, Mileshkin L, Leary A, Bessette P, Putter H, de Boer SM, Horeweg N, Nielsen M, Wezel TV, Bosse T, Creutzberg CL. Prevalence and Prognosis of Lynch Syndrome and Sporadic Mismatch Repair Deficiency in Endometrial Cancer. J Natl Cancer Inst. 2021 Sep 4;113(9):1212-1220. doi: 10.1093/jnci/djab029. PubMed 33693762 ↗
  • Lim JW, Drost L, Fazelzad R, Li Q, Huszti E, Han K, Hodgson A, Pugh TJ, Ferguson SE, Kim SR. MLH1 promoter hypermethylated endometrial cancer survival outcomes: A systematic review and meta-analysis. Gynecol Oncol. 2026 Jan;204:242-250. doi: 10.1016/j.ygyno.2025.12.005. Epub 2025 Dec 13. PubMed 41389786 ↗
  • Jamieson A, Rogan S, Zhang AW, Martin SD, Leung S, Chiu D, McRae K, Mah SJ, Kommoss S, Talhouk A, Huntsman DG, Gilks CB, McAlpine JN. Substratification of mismatch repair deficient endometrial cancers based on mechanism of MMR loss can provide prognostic and predictive refinement. Gynecol Oncol. 2026 Feb;205:105-112. doi: 10.1016/j.ygyno.2026.01.233. Epub 2026 Jan 26. PubMed 41592518 ↗
  • Addante F, d'Amati A, Santoro A, Angelico G, Inzani F, Arciuolo D, Travaglino A, Raffone A, D'Alessandris N, Scaglione G, Valente M, Tinnirello G, Sfregola S, Padial Urtueta B, Piermattei A, Cianfrini F, Mule A, Bragantini E, Zannoni GF. Mismatch Repair Deficiency as a Predictive and Prognostic Biomarker in Endometrial Cancer: A Review on Immunohistochemistry Staining Patterns and Clinical Implications. Int J Mol Sci. 2024 Jan 15;25(2):1056. doi: 10.3390/ijms25021056. PubMed 38256131 ↗
  • Leon-Castillo A, de Boer SM, Powell ME, Mileshkin LR, Mackay HJ, Leary A, Nijman HW, Singh N, Pollock PM, Bessette P, Fyles A, Haie-Meder C, Smit VTHBM, Edmondson RJ, Putter H, Kitchener HC, Crosbie EJ, de Bruyn M, Nout RA, Horeweg N, Creutzberg CL, Bosse T; TransPORTEC consortium. Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant Therapy. J Clin Oncol. 2020 Oct 10;38(29):3388-3397. doi: 10.1200/JCO.20.00549. Epub 2020 Aug 4. PubMed 32749941 ↗
  • Ledermann JA, Matias-Guiu X, Amant F, Concin N, Davidson B, Fotopoulou C, Gonzalez-Martin A, Gourley C, Leary A, Lorusso D, Banerjee S, Chiva L, Cibula D, Colombo N, Croce S, Eriksson AG, Falandry C, Fischerova D, Harter P, Joly F, Lazaro C, Lok C, Mahner S, Marme F, Marth C, McCluggage WG, McNeish IA, Morice P, Nicum S, Oaknin A, Perez-Fidalgo JA, Pignata S, Ramirez PT, Ray-Coquard I, Romero I, Scambia G, Sehouli J, Shapira-Frommer R, Sundar S, Tan DSP, Taskiran C, van Driel WJ, Vergote I, Planchamp F, Sessa C, Fagotti A. ESGO-ESMO-ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease. Ann Oncol. 2024 Mar;35(3):248-266. doi: 10.1016/j.annonc.2023.11.015. Epub 2024 Feb 1. PubMed 38307807 ↗
  • Huvila J, Gilks CB, McAlpine JN, Jamieson A. Coexistent Endometrial and Ovarian Carcinoma: Terminology, Clinicopathological Features, and Clinical Significance. Int J Gynecol Pathol. 2026 Jul 1;45(4):304-310. doi: 10.1097/PGP.0000000000001177. Epub 2026 Apr 21. PubMed 42011770 ↗
  • Jamieson A, Huvila J, Leung S, Grube M, Neilson A, Boyd N, Chiu D, Nazeran M, Anglesio MS, Senz J, Lum A, Kommoss S, Huntsman DG, Gilks CB, McAlpine JN. Co-existent endometrial and ovarian carcinoma: molecular and pathological features define low risk entity. Int J Gynecol Cancer. 2025 Aug;35(8):101957. doi: 10.1016/j.ijgc.2025.101957. Epub 2025 May 28. PubMed 40616871 ↗
  • Vermij L, Jobsen JJ, Leon-Castillo A, Brinkhuis M, Roothaan S, Powell ME, de Boer SM, Khaw P, Mileshkin LR, Fyles A, Leary A, Genestie C, Jurgenliemk-Schulz IM, Crosbie EJ, Mackay HJ, Nijman HW, Nout RA, Smit VTHBM, Creutzberg CL, Horeweg N, Bosse T; TransPORTEC Consortium. Prognostic refinement of NSMP high-risk endometrial cancers using oestrogen receptor immunohistochemistry. Br J Cancer. 2023 Mar;128(7):1360-1368. doi: 10.1038/s41416-023-02141-0. Epub 2023 Jan 23. PubMed 36690721 ↗
  • Jamieson A, Huvila J, Chiu D, Thompson EF, Scott S, Salvador S, Vicus D, Helpman L, Gotlieb W, Kean S, Samouelian V, Kobel M, Kinloch M, Parra-Harran C, Offman S, Grondin K, Irving J, Lum A, Senz J, Leung S, McConechy MK, Plante M, Kommoss S, Huntsman DG, Talhouk A, Gilks CB, McAlpine JN. Grade and Estrogen Receptor Expression Identify a Subset of No Specific Molecular Profile Endometrial Carcinomas at a Very Low Risk of Disease-Specific Death. Mod Pathol. 2023 Apr;36(4):100085. doi: 10.1016/j.modpat.2022.100085. Epub 2023 Jan 25. PubMed 36788084 ↗
  • Darbandsari A, Farahani H, Asadi M, Wiens M, Cochrane D, Khajegili Mirabadi A, Jamieson A, Farnell D, Ahmadvand P, Douglas M, Leung S, Abolmaesumi P, Jones SJM, Talhouk A, Kommoss S, Gilks CB, Huntsman DG, Singh N, McAlpine JN, Bashashati A. AI-based histopathology image analysis reveals a distinct subset of endometrial cancers. Nat Commun. 2024 Jun 26;15(1):4973. doi: 10.1038/s41467-024-49017-2. PubMed 38926357 ↗
  • Kramer P, Talhouk A, Brett MA, Chiu DS, Cairns ES, Scheunhage DA, Hammond RFL, Farnell D, Nazeran TM, Grube M, Xia Z, Senz J, Leung S, Feil L, Pasternak J, Dixon K, Hartkopf A, Kramer B, Brucker S, Heitz F, du Bois A, Harter P, Kommoss FKF, Sinn HP, Heublein S, Kommoss F, Vollert HW, Manchanda R, de Kroon CD, Nijman HW, de Bruyn M, Thompson EF, Bashashati A, McAlpine JN, Singh N, Tinker AV, Staebler A, Bosse T, Kommoss S, Kobel M, Anglesio MS. Endometrial Cancer Molecular Risk Stratification is Equally Prognostic for Endometrioid Ovarian Carcinoma. Clin Cancer Res. 2020 Oct 15;26(20):5400-5410. doi: 10.1158/1078-0432.CCR-20-1268. Epub 2020 Jul 31. PubMed 32737030 ↗
  • Cybulska P, Paula ADC, Tseng J, Leitao MM Jr, Bashashati A, Huntsman DG, Nazeran TM, Aghajanian C, Abu-Rustum NR, DeLair DF, Shah SP, Weigelt B. Molecular profiling and molecular classification of endometrioid ovarian carcinomas. Gynecol Oncol. 2019 Sep;154(3):516-523. doi: 10.1016/j.ygyno.2019.07.012. Epub 2019 Jul 21. PubMed 31340883 ↗
  • Talhouk A, McConechy MK, Leung S, Yang W, Lum A, Senz J, Boyd N, Pike J, Anglesio M, Kwon JS, Karnezis AN, Huntsman DG, Gilks CB, McAlpine JN. Confirmation of ProMisE: A simple, genomics-based clinical classifier for endometrial cancer. Cancer. 2017 Mar 1;123(5):802-813. doi: 10.1002/cncr.30496. Epub 2017 Jan 6. PubMed 28061006 ↗
  • Talhouk A, McConechy MK, Leung S, Li-Chang HH, Kwon JS, Melnyk N, Yang W, Senz J, Boyd N, Karnezis AN, Huntsman DG, Gilks CB, McAlpine JN. A clinically applicable molecular-based classification for endometrial cancers. Br J Cancer. 2015 Jul 14;113(2):299-310. doi: 10.1038/bjc.2015.190. Epub 2015 Jun 30. PubMed 26172027 ↗
  • Stelloo E, Nout RA, Osse EM, Jurgenliemk-Schulz IJ, Jobsen JJ, Lutgens LC, van der Steen-Banasik EM, Nijman HW, Putter H, Bosse T, Creutzberg CL, Smit VT. Improved Risk Assessment by Integrating Molecular and Clinicopathological Factors in Early-stage Endometrial Cancer-Combined Analysis of the PORTEC Cohorts. Clin Cancer Res. 2016 Aug 15;22(16):4215-24. doi: 10.1158/1078-0432.CCR-15-2878. Epub 2016 Mar 22. PubMed 27006490 ↗
  • Oaknin A, Bosse TJ, Creutzberg CL, Giornelli G, Harter P, Joly F, Lorusso D, Marth C, Makker V, Mirza MR, Ledermann JA, Colombo N; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Endometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022 Sep;33(9):860-877. doi: 10.1016/j.annonc.2022.05.009. Epub 2022 Jun 8. No abstract available. PubMed 35690222 ↗
  • Kommoss S, McConechy MK, Kommoss F, Leung S, Bunz A, Magrill J, Britton H, Kommoss F, Grevenkamp F, Karnezis A, Yang W, Lum A, Kramer B, Taran F, Staebler A, Lax S, Brucker SY, Huntsman DG, Gilks CB, McAlpine JN, Talhouk A. Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case series. Ann Oncol. 2018 May 1;29(5):1180-1188. doi: 10.1093/annonc/mdy058. PubMed 29432521 ↗
  • Jamieson A, Huvila J, Leung S, Chiu D, Thompson EF, Lum A, Kinloch M, Helpman L, Salvador S, Vicus D, Kean S, Samouelian V, Grondin K, Irving J, Offman S, Parra-Herran C, Lau S, Scott S, Plante M, McConechy MK, Huntsman DG, Talhouk A, Kommoss S, Gilks CB, McAlpine JN. Molecular subtype stratified outcomes according to adjuvant therapy in endometrial cancer. Gynecol Oncol. 2023 Mar;170:282-289. doi: 10.1016/j.ygyno.2023.01.025. Epub 2023 Feb 6. PubMed 36753816 ↗
  • Berek JS, Matias-Guiu X, Creutzberg C, Fotopoulou C, Gaffney D, Kehoe S, Lindemann K, Mutch D, Concin N; Endometrial Cancer Staging Subcommittee, FIGO Women's Cancer Committee. FIGO staging of endometrial cancer: 2023. Int J Gynaecol Obstet. 2023 Aug;162(2):383-394. doi: 10.1002/ijgo.14923. Epub 2023 Jun 20. PubMed 37337978 ↗
  • Hohn AK, Brambs CE, Hiller GGR, May D, Schmoeckel E, Horn LC. 2020 WHO Classification of Female Genital Tumors. Geburtshilfe Frauenheilkd. 2021 Oct;81(10):1145-1153. doi: 10.1055/a-1545-4279. Epub 2021 Oct 6. PubMed 34629493 ↗
  • Turashvili G, Gomez-Hidalgo NR, Flynn J, Gonen M, Leitao MM Jr, Soslow RA, Murali R. Risk-based stratification of carcinomas concurrently involving the endometrium and ovary. Gynecol Oncol. 2019 Jan;152(1):38-45. doi: 10.1016/j.ygyno.2018.10.033. Epub 2018 Nov 6. PubMed 30413340 ↗
  • Soliman PT, Slomovitz BM, Broaddus RR, Sun CC, Oh JC, Eifel PJ, Gershenson DM, Lu KH. Synchronous primary cancers of the endometrium and ovary: a single institution review of 84 cases. Gynecol Oncol. 2004 Aug;94(2):456-62. doi: 10.1016/j.ygyno.2004.05.006. PubMed 15297188 ↗
  • Concin N, Matias-Guiu X, Vergote I, Cibula D, Mirza MR, Marnitz S, Ledermann J, Bosse T, Chargari C, Fagotti A, Fotopoulou C, Gonzalez Martin A, Lax S, Lorusso D, Marth C, Morice P, Nout RA, O'Donnell D, Querleu D, Raspollini MR, Sehouli J, Sturdza A, Taylor A, Westermann A, Wimberger P, Colombo N, Planchamp F, Creutzberg CL. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. Int J Gynecol Cancer. 2021 Jan;31(1):12-39. doi: 10.1136/ijgc-2020-002230. Epub 2020 Dec 18. PubMed 33397713 ↗
  • Creutzberg CL, Kim JW, Eminowicz G, Allanson E, Eberst L, Kim SI, Nout RA, Park JY, Lorusso D, Mileshkin L, Ottevanger PB, Brand A, Mezzanzanica D, Oza A, Gebski V, Pothuri B, Batley T, Gordon C, Mitra T, White H, Howitt B, Matias-Guiu X, Ray-Coquard I, Gaffney D, Small W Jr, Miller A, Concin N, Powell MA, Stuart G, Bookman MA; participants of the 2023 Gynecologic Cancer InterGroup Endometrial Cancer Consensus Conference on Clinical Research. Clinical research in endometrial cancer: consensus recommendations from the Gynecologic Cancer InterGroup. Lancet Oncol. 2024 Sep;25(9):e420-e431. doi: 10.1016/S1470-2045(24)00192-X. PubMed 39214113 ↗
  • Schultheis AM, Ng CK, De Filippo MR, Piscuoglio S, Macedo GS, Gatius S, Perez Mies B, Soslow RA, Lim RS, Viale A, Huberman KH, Palacios JC, Reis-Filho JS, Matias-Guiu X, Weigelt B. Massively Parallel Sequencing-Based Clonality Analysis of Synchronous Endometrioid Endometrial and Ovarian Carcinomas. J Natl Cancer Inst. 2016 Feb 1;108(6):djv427. doi: 10.1093/jnci/djv427. Print 2016 Jun. PubMed 26832770 ↗
  • Guerriero A, Moro M, Angerilli V, Munari G, Santoro L, Alessandrini L, Favero L, Tasca G, Fassan M, Dei Tos AP. Synchronous Endometrial and Ovarian Carcinomas: Pathologic and Molecular Analysis Highlights the Monoclonal Origin of the Lesions. Int J Gynecol Pathol. 2024 Jul 1;43(4):309-315. doi: 10.1097/PGP.0000000000000982. Epub 2023 Sep 8. PubMed 37922918 ↗
  • Anglesio MS, Wang YK, Maassen M, Horlings HM, Bashashati A, Senz J, Mackenzie R, Grewal DS, Li-Chang H, Karnezis AN, Sheffield BS, McConechy MK, Kommoss F, Taran FA, Staebler A, Shah SP, Wallwiener D, Brucker S, Gilks CB, Kommoss S, Huntsman DG. Synchronous Endometrial and Ovarian Carcinomas: Evidence of Clonality. J Natl Cancer Inst. 2016 Feb 1;108(6):djv428. doi: 10.1093/jnci/djv428. Print 2016 Jun. PubMed 26832771 ↗
  • Liu J, Berchuck A, Backes FJ, Cohen J, Grisham R, Leath CA, Martin L, Matei D, Miller DS, Robertson S, Barroilhet L, Uppal S, Hendrickson AW, Gershenson DM, Gray HJ, Hakam A, Jain A, Konecny GE, Moroney J, Ratner E, Schorge J, Thaker PH, Werner TL, Zsiros E, Behbakht K, Chen LM, DeRosa M, Eisenhauer EL, Leiserowitz G, Litkouhi B, McHale M, Percac-Lima S, Rodabaugh K, Vargas R, Jones F, Kovach E, Hang L, Ramakrishnan S, Alvarez RD, Armstrong DK. NCCN Guidelines(R) Insights: Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer, Version 3.2024. J Natl Compr Canc Netw. 2024 Oct;22(8):512-519. doi: 10.6004/jnccn.2024.0052. PubMed 39413835 ↗
  • de Nonneville A, Kalbacher E, Cannone F, Guille A, Adelaide J, Finetti P, Cappiello M, Lambaudie E, Ettore G, Charafe E, Mamessier E, Provansal M, Bertucci F, Sabatier R. Endometrioid ovarian carcinoma landscape: pathological and molecular characterization. Mol Oncol. 2024 Oct;18(10):2586-2600. doi: 10.1002/1878-0261.13679. Epub 2024 Jun 25. PubMed 38923749 ↗

Individual participant data

Plan to share: Yes — Other researchers can request data from the PI's (McAlpine and Jamieson) directly

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: From study start to 5 years from study completion, estimated.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Oct 2032, 72 months later.

Of 228 non-industry phase 2 interventional studies under Ovarian Neoplasms, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 80. This study's planned 72 months is above that.

Counting every sponsor, half of 344 studies reached it within 47 months; a quarter within 33 and three quarters within 72.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 2, 2026
First posted
Nov 16, 2026
StartEst.
Oct 30, 2026
Primary completionEst.
Oct 30, 2032
CompletionEst.
Oct 30, 2032
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07940062
Collaborators
University of British Columbia, Gynecologic Cancer Initiative - Clinical Trials Group (GCI-CTG), Ovarian Cancer Canada
Responsible party
Jessica McAlpine (Division Head, Chew Wei Chair in Gynecologic Oncology, British Columbia Cancer Agency) — Principal investigator
First posted
Nov 16, 2026
Start date
Oct 30, 2026 (estimated)
Primary completion
Oct 30, 2032 (estimated)
Completion
Oct 30, 2032 (estimated)
Last update
Nov 16, 2026

Study contacts

Kiana Burran
Contact
kiana.burran@ubc.ca
1+ 604-875-4411 ext. 63530
Jessica McAlpine
principal investigator · British Columbia Cancer Agency
Amy Jamieson
principal investigator · British Columbia Cancer Agency

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion